View Older Stories View More Recent Stories

Jul 27, 2020 06:30AM Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
Jul 21, 2020 04:45PM Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
Jul 21, 2020 04:45PM Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
Jul 16, 2020 06:30AM Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
Jul 16, 2020 06:30AM Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
Jul 8, 2020 09:02AM Emergent BioSolutions (EBS), Mount Sinai Health System and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Depart
Jul 8, 2020 09:00AM Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department
Jul 8, 2020 09:00AM Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department
Jul 6, 2020 06:31AM Emergent BioSolutions (EBS) Signs 5-Year Agreement for Large-Scale Drug Substance Manufacturing for J&J’s (JNJ) Lead COVID-19 Vaccine Candidate
Jul 6, 2020 06:30AM Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   
Jul 6, 2020 06:30AM Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   
Jun 18, 2020 06:30AM Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Jun 18, 2020 06:30AM Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Jun 16, 2020 04:05PM Emergent BioSolutions to Participate in Virtual Investor Conferences
Jun 16, 2020 04:05PM Emergent BioSolutions to Participate in Virtual Investor Conferences
Jun 11, 2020 08:48AM Emergent BioSolutions (EBS) Announces Pact to be U.S. Manufacturing Partner for AstraZeneca's (AZN) COVID-19 Vaccine Candidate
Jun 11, 2020 08:48AM Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
Jun 11, 2020 08:47AM Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
Jun 5, 2020 07:39PM Emergent BioSolutions Statement on U.S. District Court Decision
Jun 1, 2020 06:37AM UPDATE: Emergent BioSolutions (EBS) Announces Expanded BARDA Contract to Join 'Warp Speed Program' for COVID-19 Vaccine Development and Manufacturing
Jun 1, 2020 06:30AM Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
Jun 1, 2020 06:30AM Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
May 12, 2020 06:00AM Emergent BioSolutions to Participate in Virtual Investor Conferences
May 12, 2020 06:00AM Emergent BioSolutions to Participate in Virtual Investor Conferences
May 7, 2020 09:20AM Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
May 7, 2020 09:20AM Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
Apr 30, 2020 04:08PM Emergent BioSolutions Reports Financial Results for First Quarter 2020
Apr 30, 2020 04:08PM Emergent BioSolutions Reports Financial Results for First Quarter 2020
Apr 23, 2020 06:51PM Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
Apr 23, 2020 06:51PM Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
Apr 21, 2020 04:56PM Emergent BioSolutions (EBS) Appoints Dr. Karen L. Smith as Chief Medical Officer
Apr 21, 2020 04:55PM Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
Apr 21, 2020 04:55PM Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
Apr 16, 2020 06:30AM Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
Apr 16, 2020 06:30AM Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
Apr 6, 2020 06:30AM Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
Apr 6, 2020 06:30AM Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
Apr 2, 2020 04:22PM Emergent BioSolutions (EBS) Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
Apr 2, 2020 04:05PM Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
Apr 2, 2020 04:05PM Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
Mar 31, 2020 05:37PM Emergent BioSolutions (EBS) Enters Agreement with Novavax (NVAX) to Manufacture NanoFlu
Mar 31, 2020 04:05PM Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
Mar 31, 2020 04:05PM Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
Mar 18, 2020 06:30AM EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
Mar 18, 2020 06:30AM EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
Mar 11, 2020 04:23PM Emergent BioSolutions (EBS) Initiated Development of Two Products for COVID-19
Mar 11, 2020 04:21PM Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
Mar 11, 2020 04:21PM Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
Mar 10, 2020 06:01AM Emergent BioSolutions (EBS) Reports Development & Manufacturing Agreement With Novavax (NVAX) for Experimental Vaccine Candidate for Coronavirus Disease
Mar 10, 2020 05:30AM Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
View More Recent Stories View Older Stories